The addition of β-adrenergic receptor antagonists to a medical regimen for heart failure that includes angiotensin-converting enzyme (ACE) inhibitors as background therapy has been associated ...

The global Benign Prostatic Hyperplasia Surgical Treatment market, valued at US$11.92 billion in 2023, is forecasted to grow at a robust CAGR of 5.3%, reaching US$12.62 billion in 2024 and an ...

The global Benign Prostatic Hyperplasia Surgical Treatment market, valued at US$11.92 billion in 2023, is forecasted to grow at a robust CAGR ...